IGC

IGC Pharma, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$0.18

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %3.6 / %30

Non-compliant assets / Total market cap %0.1 / %30

Non-compliant revenue / Total income %4.2 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Website

Analysis (Turkish): IGC Hissesi Caiz mi, Helal mi? IGC Pharma, Inc. Katılım Analizi